Physician profile
Brian Jack Gilbert
NPI 1144993585
$6,129.79
in general payments reported to CMS, 2019-2025
32 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $1,891 · 2023: $1,797 · 2024: $1,386 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,857.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,193.14 | 2021-2025 | Farxiga, Lokelma, Breztri |
| Abbvie INC. | $1,030.28 | 2021-2025 | |
| Pfizer INC. | $749.31 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.79 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $465.94 | 2021-2024 | |
| Novo Nordisk INC | $356.53 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $267.72 | 2021-2024 | Nucala, Pediarix, Shingrix |
| Sanofi-Aventis U.S. LLC | $230.83 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $126.24 | 2021-2022 | |
| Amgen INC. | $116.88 | 2022-2024 | Otezla, Repatha, Evenity |
| Vanda Pharmaceuticals INC. | $109.03 | 2021-2023 | Hetlioz |
| Biohaven Pharmaceutical Holding Company LTD. | $106.94 | 2022 | |
| Lilly USA, LLC | $92.13 | 2022-2023 | Mounjaro |
| Sumitomo Pharma America, INC. | $79.50 | 2023-2024 | Gemtesa |
| Lundbeck LLC | $78.01 | 2022-2024 | Rexulti |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $75.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $74.10 | 2022-2024 | |
| Exact Sciences Corporation | $63.66 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $59.93 | 2022-2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $53.39 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $52.54 | 2024 | Veozah |
| Mylan Specialty L.P. | $35.65 | 2023 | Yupelri |
| Merck Sharp & Dohme LLC | $32.14 | 2022-2024 | Gardasil 9, Gardasil, Rotateq |
| Sanofi Pasteur INC. | $30.44 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $25.22 | 2023 | Ingrezza |
| Clarus Therapeutics INC. | $19.65 | 2021 | |
| Antares Pharma, INC. | $18.10 | 2021 | |
| Daiichi Sankyo INC. | $15.81 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.67 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2022 | |
| Dexcom, INC. | $14.59 | 2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $14.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gilbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.